ARTICLE | Tools & Techniques
Using exosomes to switch myeloid cells
Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer
December 5, 2019 9:06 PM UTC
Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer.
The biotech presented preclinical data Nov. 18 at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy showing that ASO-carrying exosome therapies can be an effective monotherapy in cancer. ...
BCIQ Company Profiles